Switch theme
Sign up to access all valuation multiples
Jamjoom Pharmaceuticals Factory Co is engaged in the development, manufacture, and marketing of a wide range of high-quality branded generic pharmaceuticals, including pharmaceuticals and consumer health products, with the majority of revenue coming from pharmaceutical sales. Geographically the company has a presence in the Kingdom of Saudi Arabia, the Gulf, Iraq, Egypt, North Africa, and other export markets.
1994
1.1K+
LTM Revenue $367M
LTM EBITDA $120M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jamjoom Pharma has a last 12-month revenue of $367M and a last 12-month EBITDA of $120M.
In the most recent fiscal year, Jamjoom Pharma achieved revenue of $352M and an EBITDA of $112M.
Jamjoom Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jamjoom Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $294M | $352M | XXX | XXX | XXX |
| Gross Profit | $159M | $188M | XXX | XXX | XXX |
| Gross Margin | 54% | 53% | XXX | XXX | XXX |
| EBITDA | $91.4M | $112M | XXX | XXX | XXX |
| EBITDA Margin | 31% | 32% | XXX | XXX | XXX |
| Net Profit | $45.7M | $78.0M | XXX | XXX | XXX |
| Net Margin | 16% | 22% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Jamjoom Pharma's stock price is SAR 153 (or $41).
Jamjoom Pharma has current market cap of SAR 10.7B (or $2.9B), and EV of SAR 10.5B (or $2.8B).
See Jamjoom Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $2.9B | XXX | XXX | XXX | XXX | $1.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Jamjoom Pharma has market cap of $2.9B and EV of $2.8B.
Jamjoom Pharma's trades at 7.6x LTM EV/Revenue multiple, and 23.3x LTM EBITDA.
Analysts estimate Jamjoom Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jamjoom Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 7.9x | XXX | XXX | XXX |
| EV/EBITDA | 24.9x | XXX | XXX | XXX |
| P/E | 30.1x | XXX | XXX | XXX |
| P/E/Growth | 2.1x | XXX | XXX | XXX |
| EV/FCF | 50.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJamjoom Pharma's NTM/LTM revenue growth is 14%
Jamjoom Pharma's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Jamjoom Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jamjoom Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jamjoom Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 46% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 31% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jamjoom Pharma acquired XXX companies to date.
Last acquisition by Jamjoom Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Jamjoom Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jamjoom Pharma founded? | Jamjoom Pharma was founded in 1994. |
| Where is Jamjoom Pharma headquartered? | Jamjoom Pharma is headquartered in Saudi Arabia. |
| How many employees does Jamjoom Pharma have? | As of today, Jamjoom Pharma has 1.1K+ employees. |
| Is Jamjoom Pharma publicy listed? | Yes, Jamjoom Pharma is a public company listed on SAU. |
| What is the stock symbol of Jamjoom Pharma? | Jamjoom Pharma trades under 4015 ticker. |
| When did Jamjoom Pharma go public? | Jamjoom Pharma went public in 2023. |
| Who are competitors of Jamjoom Pharma? | Similar companies to Jamjoom Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Jamjoom Pharma? | Jamjoom Pharma's current market cap is $2.9B |
| What is the current revenue of Jamjoom Pharma? | Jamjoom Pharma's last 12-month revenue is $367M. |
| What is the current EBITDA of Jamjoom Pharma? | Jamjoom Pharma's last 12-month EBITDA is $120M. |
| What is the current EV/Revenue multiple of Jamjoom Pharma? | Current revenue multiple of Jamjoom Pharma is 7.6x. |
| What is the current EV/EBITDA multiple of Jamjoom Pharma? | Current EBITDA multiple of Jamjoom Pharma is 23.3x. |
| What is the current revenue growth of Jamjoom Pharma? | Jamjoom Pharma revenue growth between 2023 and 2024 was 20%. |
| Is Jamjoom Pharma profitable? | Yes, Jamjoom Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
